The global market for Immune Checkpoint Inhibitors was valued at US$ 16860 million in the year 2024 and is projected to reach a revised size of US$ 47210 million by 2031, growing at a CAGR of 16.1% during the forecast period.

Immune Checkpoint Inhibitors Market

Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.

North American market for Immune Checkpoint Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Immune Checkpoint Inhibitors is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Immune Checkpoint Inhibitors include Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Immune Checkpoint Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immune Checkpoint Inhibitors.

The Immune Checkpoint Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Immune Checkpoint Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Immune Checkpoint Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Immune Checkpoint Inhibitors Market Report

Report Metric	Details
Report Name	Immune Checkpoint Inhibitors Market
Accounted market size in year	US$ 16860 million
Forecasted market size in 2031	US$ 47210 million
CAGR	16.1%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	PD-1/PD-L1 CTLA-4
Segment by Application	Lung Cancer Colorectal Cancer Breast Cancer Prostate Cancer Melanoma Blood Cancer Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Immune Checkpoint Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Immune Checkpoint Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Immune Checkpoint Inhibitors Market growing?

Ans: The Immune Checkpoint Inhibitors Market witnessing a CAGR of 16.1% during the forecast period 2025-2031.

What is the Immune Checkpoint Inhibitors Market size in 2031?

Ans: The Immune Checkpoint Inhibitors Market size in 2031 will be US$ 47210 million.

Who are the main players in the Immune Checkpoint Inhibitors Market report?

Ans: The main players in the Immune Checkpoint Inhibitors Market are Bristol Myer Squibb, AstraZeneca, Merck, Roche / Genentech, Ono Pharmaceutical, Regeneron, Innovent, Hengrui Medicine, Junshi Biosciences

What are the Application segmentation covered in the Immune Checkpoint Inhibitors Market report?

Ans: The Applications covered in the Immune Checkpoint Inhibitors Market report are Lung Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Melanoma, Blood Cancer, Other

What are the Type segmentation covered in the Immune Checkpoint Inhibitors Market report?

Ans: The Types covered in the Immune Checkpoint Inhibitors Market report are PD-1/PD-L1, CTLA-4

1 Immune Checkpoint Inhibitors Market Overview

1.1 Product Definition

1.2 Immune Checkpoint Inhibitors by Type

1.2.1 Global Immune Checkpoint Inhibitors Market Value Comparison by Type (2024 VS 2031)

1.2.2 PD-1/PD-L1

1.2.3 CTLA-4

1.3 Immune Checkpoint Inhibitors by Application

1.3.1 Global Immune Checkpoint Inhibitors Market Value by Application (2024 VS 2031)

1.3.2 Lung Cancer

1.3.3 Colorectal Cancer

1.3.4 Breast Cancer

1.3.5 Prostate Cancer

1.3.6 Melanoma

1.3.7 Blood Cancer

1.3.8 Other

1.4 Global Immune Checkpoint Inhibitors Market Size Estimates and Forecasts

1.4.1 Global Immune Checkpoint Inhibitors Revenue 2020-2031

1.4.2 Global Immune Checkpoint Inhibitors Sales 2020-2031

1.4.3 Global Immune Checkpoint Inhibitors Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Immune Checkpoint Inhibitors Market Competition by Manufacturers

2.1 Global Immune Checkpoint Inhibitors Sales Market Share by Manufacturers (2020-2025)

2.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Immune Checkpoint Inhibitors Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Immune Checkpoint Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Immune Checkpoint Inhibitors, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Immune Checkpoint Inhibitors, Product Type & Application

2.7 Global Key Manufacturers of Immune Checkpoint Inhibitors, Date of Enter into This Industry

2.8 Global Immune Checkpoint Inhibitors Market Competitive Situation and Trends

2.8.1 Global Immune Checkpoint Inhibitors Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Immune Checkpoint Inhibitors Players Market Share by Revenue

2.8.3 Global Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Immune Checkpoint Inhibitors Market Scenario by Region

3.1 Global Immune Checkpoint Inhibitors Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Immune Checkpoint Inhibitors Sales by Region: 2020-2031

3.2.1 Global Immune Checkpoint Inhibitors Sales by Region: 2020-2025

3.2.2 Global Immune Checkpoint Inhibitors Sales by Region: 2026-2031

3.3 Global Immune Checkpoint Inhibitors Revenue by Region: 2020-2031

3.3.1 Global Immune Checkpoint Inhibitors Revenue by Region: 2020-2025

3.3.2 Global Immune Checkpoint Inhibitors Revenue by Region: 2026-2031

3.4 North America Immune Checkpoint Inhibitors Market Facts & Figures by Country

3.4.1 North America Immune Checkpoint Inhibitors Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Immune Checkpoint Inhibitors Sales by Country (2020-2031)

3.4.3 North America Immune Checkpoint Inhibitors Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Immune Checkpoint Inhibitors Market Facts & Figures by Country

3.5.1 Europe Immune Checkpoint Inhibitors Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Immune Checkpoint Inhibitors Sales by Country (2020-2031)

3.5.3 Europe Immune Checkpoint Inhibitors Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Immune Checkpoint Inhibitors Market Facts & Figures by Region

3.6.1 Asia Pacific Immune Checkpoint Inhibitors Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Immune Checkpoint Inhibitors Sales by Region (2020-2031)

3.6.3 Asia Pacific Immune Checkpoint Inhibitors Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Immune Checkpoint Inhibitors Market Facts & Figures by Country

3.7.1 Latin America Immune Checkpoint Inhibitors Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Immune Checkpoint Inhibitors Sales by Country (2020-2031)

3.7.3 Latin America Immune Checkpoint Inhibitors Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Immune Checkpoint Inhibitors Market Facts & Figures by Country

3.8.1 Middle East and Africa Immune Checkpoint Inhibitors Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Immune Checkpoint Inhibitors Sales by Country (2020-2031)

3.8.3 Middle East and Africa Immune Checkpoint Inhibitors Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Immune Checkpoint Inhibitors Sales by Type (2020-2031)

4.1.1 Global Immune Checkpoint Inhibitors Sales by Type (2020-2025)

4.1.2 Global Immune Checkpoint Inhibitors Sales by Type (2026-2031)

4.1.3 Global Immune Checkpoint Inhibitors Sales Market Share by Type (2020-2031)

4.2 Global Immune Checkpoint Inhibitors Revenue by Type (2020-2031)

4.2.1 Global Immune Checkpoint Inhibitors Revenue by Type (2020-2025)

4.2.2 Global Immune Checkpoint Inhibitors Revenue by Type (2026-2031)

4.2.3 Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2020-2031)

4.3 Global Immune Checkpoint Inhibitors Price by Type (2020-2031)

5 Segment by Application

5.1 Global Immune Checkpoint Inhibitors Sales by Application (2020-2031)

5.1.1 Global Immune Checkpoint Inhibitors Sales by Application (2020-2025)

5.1.2 Global Immune Checkpoint Inhibitors Sales by Application (2026-2031)

5.1.3 Global Immune Checkpoint Inhibitors Sales Market Share by Application (2020-2031)

5.2 Global Immune Checkpoint Inhibitors Revenue by Application (2020-2031)

5.2.1 Global Immune Checkpoint Inhibitors Revenue by Application (2020-2025)

5.2.2 Global Immune Checkpoint Inhibitors Revenue by Application (2026-2031)

5.2.3 Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2020-2031)

5.3 Global Immune Checkpoint Inhibitors Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Bristol Myer Squibb

6.1.1 Bristol Myer Squibb Company Information

6.1.2 Bristol Myer Squibb Description and Business Overview

6.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Bristol Myer Squibb Immune Checkpoint Inhibitors Product Portfolio

6.1.5 Bristol Myer Squibb Recent Developments/Updates

6.2 AstraZeneca

6.2.1 AstraZeneca Company Information

6.2.2 AstraZeneca Description and Business Overview

6.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.2.4 AstraZeneca Immune Checkpoint Inhibitors Product Portfolio

6.2.5 AstraZeneca Recent Developments/Updates

6.3 Merck

6.3.1 Merck Company Information

6.3.2 Merck Description and Business Overview

6.3.3 Merck Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Merck Immune Checkpoint Inhibitors Product Portfolio

6.3.5 Merck Recent Developments/Updates

6.4 Roche / Genentech

6.4.1 Roche / Genentech Company Information

6.4.2 Roche / Genentech Description and Business Overview

6.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Roche / Genentech Immune Checkpoint Inhibitors Product Portfolio

6.4.5 Roche / Genentech Recent Developments/Updates

6.5 Ono Pharmaceutical

6.5.1 Ono Pharmaceutical Company Information

6.5.2 Ono Pharmaceutical Description and Business Overview

6.5.3 Ono Pharmaceutical Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Ono Pharmaceutical Immune Checkpoint Inhibitors Product Portfolio

6.5.5 Ono Pharmaceutical Recent Developments/Updates

6.6 Regeneron

6.6.1 Regeneron Company Information

6.6.2 Regeneron Description and Business Overview

6.6.3 Regeneron Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Regeneron Immune Checkpoint Inhibitors Product Portfolio

6.6.5 Regeneron Recent Developments/Updates

6.7 Innovent

6.7.1 Innovent Company Information

6.7.2 Innovent Description and Business Overview

6.7.3 Innovent Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Innovent Immune Checkpoint Inhibitors Product Portfolio

6.7.5 Innovent Recent Developments/Updates

6.8 Hengrui Medicine

6.8.1 Hengrui Medicine Company Information

6.8.2 Hengrui Medicine Description and Business Overview

6.8.3 Hengrui Medicine Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Hengrui Medicine Immune Checkpoint Inhibitors Product Portfolio

6.8.5 Hengrui Medicine Recent Developments/Updates

6.9 Junshi Biosciences

6.9.1 Junshi Biosciences Company Information

6.9.2 Junshi Biosciences Description and Business Overview

6.9.3 Junshi Biosciences Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Junshi Biosciences Immune Checkpoint Inhibitors Product Portfolio

6.9.5 Junshi Biosciences Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Immune Checkpoint Inhibitors Industry Chain Analysis

7.2 Immune Checkpoint Inhibitors Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Immune Checkpoint Inhibitors Production Mode & Process Analysis

7.4 Immune Checkpoint Inhibitors Sales and Marketing

7.4.1 Immune Checkpoint Inhibitors Sales Channels

7.4.2 Immune Checkpoint Inhibitors Distributors

7.5 Immune Checkpoint Inhibitors Customer Analysis

8 Immune Checkpoint Inhibitors Market Dynamics

8.1 Immune Checkpoint Inhibitors Industry Trends

8.2 Immune Checkpoint Inhibitors Market Drivers

8.3 Immune Checkpoint Inhibitors Market Challenges

8.4 Immune Checkpoint Inhibitors Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Immune Checkpoint Inhibitors Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Immune Checkpoint Inhibitors Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Immune Checkpoint Inhibitors Market Competitive Situation by Manufacturers in 2024

Table 4. Global Immune Checkpoint Inhibitors Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Immune Checkpoint Inhibitors Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Immune Checkpoint Inhibitors Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Immune Checkpoint Inhibitors Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Immune Checkpoint Inhibitors Average Price (USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Immune Checkpoint Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Immune Checkpoint Inhibitors, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Immune Checkpoint Inhibitors, Product Type & Application

Table 12. Global Key Manufacturers of Immune Checkpoint Inhibitors, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Immune Checkpoint Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immune Checkpoint Inhibitors as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Immune Checkpoint Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Immune Checkpoint Inhibitors Sales by Region (2020-2025) & (K Units)

Table 18. Global Immune Checkpoint Inhibitors Sales Market Share by Region (2020-2025)

Table 19. Global Immune Checkpoint Inhibitors Sales by Region (2026-2031) & (K Units)

Table 20. Global Immune Checkpoint Inhibitors Sales Market Share by Region (2026-2031)

Table 21. Global Immune Checkpoint Inhibitors Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Immune Checkpoint Inhibitors Revenue Market Share by Region (2020-2025)

Table 23. Global Immune Checkpoint Inhibitors Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Immune Checkpoint Inhibitors Revenue Market Share by Region (2026-2031)

Table 25. North America Immune Checkpoint Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Immune Checkpoint Inhibitors Sales by Country (2020-2025) & (K Units)

Table 27. North America Immune Checkpoint Inhibitors Sales by Country (2026-2031) & (K Units)

Table 28. North America Immune Checkpoint Inhibitors Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Immune Checkpoint Inhibitors Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Immune Checkpoint Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Immune Checkpoint Inhibitors Sales by Country (2020-2025) & (K Units)

Table 32. Europe Immune Checkpoint Inhibitors Sales by Country (2026-2031) & (K Units)

Table 33. Europe Immune Checkpoint Inhibitors Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Immune Checkpoint Inhibitors Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Immune Checkpoint Inhibitors Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Immune Checkpoint Inhibitors Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Immune Checkpoint Inhibitors Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Immune Checkpoint Inhibitors Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Immune Checkpoint Inhibitors Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Immune Checkpoint Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Immune Checkpoint Inhibitors Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Immune Checkpoint Inhibitors Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Immune Checkpoint Inhibitors Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Immune Checkpoint Inhibitors Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Immune Checkpoint Inhibitors Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Immune Checkpoint Inhibitors Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Immune Checkpoint Inhibitors Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Immune Checkpoint Inhibitors Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Immune Checkpoint Inhibitors Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Immune Checkpoint Inhibitors Sales (K Units) by Type (2020-2025)

Table 51. Global Immune Checkpoint Inhibitors Sales (K Units) by Type (2026-2031)

Table 52. Global Immune Checkpoint Inhibitors Sales Market Share by Type (2020-2025)

Table 53. Global Immune Checkpoint Inhibitors Sales Market Share by Type (2026-2031)

Table 54. Global Immune Checkpoint Inhibitors Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Immune Checkpoint Inhibitors Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2020-2025)

Table 57. Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2026-2031)

Table 58. Global Immune Checkpoint Inhibitors Price (USD/Unit) by Type (2020-2025)

Table 59. Global Immune Checkpoint Inhibitors Price (USD/Unit) by Type (2026-2031)

Table 60. Global Immune Checkpoint Inhibitors Sales (K Units) by Application (2020-2025)

Table 61. Global Immune Checkpoint Inhibitors Sales (K Units) by Application (2026-2031)

Table 62. Global Immune Checkpoint Inhibitors Sales Market Share by Application (2020-2025)

Table 63. Global Immune Checkpoint Inhibitors Sales Market Share by Application (2026-2031)

Table 64. Global Immune Checkpoint Inhibitors Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Immune Checkpoint Inhibitors Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2020-2025)

Table 67. Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2026-2031)

Table 68. Global Immune Checkpoint Inhibitors Price (USD/Unit) by Application (2020-2025)

Table 69. Global Immune Checkpoint Inhibitors Price (USD/Unit) by Application (2026-2031)

Table 70. Bristol Myer Squibb Company Information

Table 71. Bristol Myer Squibb Description and Business Overview

Table 72. Bristol Myer Squibb Immune Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 73. Bristol Myer Squibb Immune Checkpoint Inhibitors Product

Table 74. Bristol Myer Squibb Recent Developments/Updates

Table 75. AstraZeneca Company Information

Table 76. AstraZeneca Description and Business Overview

Table 77. AstraZeneca Immune Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 78. AstraZeneca Immune Checkpoint Inhibitors Product

Table 79. AstraZeneca Recent Developments/Updates

Table 80. Merck Company Information

Table 81. Merck Description and Business Overview

Table 82. Merck Immune Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 83. Merck Immune Checkpoint Inhibitors Product

Table 84. Merck Recent Developments/Updates

Table 85. Roche / Genentech Company Information

Table 86. Roche / Genentech Description and Business Overview

Table 87. Roche / Genentech Immune Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 88. Roche / Genentech Immune Checkpoint Inhibitors Product

Table 89. Roche / Genentech Recent Developments/Updates

Table 90. Ono Pharmaceutical Company Information

Table 91. Ono Pharmaceutical Description and Business Overview

Table 92. Ono Pharmaceutical Immune Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 93. Ono Pharmaceutical Immune Checkpoint Inhibitors Product

Table 94. Ono Pharmaceutical Recent Developments/Updates

Table 95. Regeneron Company Information

Table 96. Regeneron Description and Business Overview

Table 97. Regeneron Immune Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 98. Regeneron Immune Checkpoint Inhibitors Product

Table 99. Regeneron Recent Developments/Updates

Table 100. Innovent Company Information

Table 101. Innovent Description and Business Overview

Table 102. Innovent Immune Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 103. Innovent Immune Checkpoint Inhibitors Product

Table 104. Innovent Recent Developments/Updates

Table 105. Hengrui Medicine Company Information

Table 106. Hengrui Medicine Description and Business Overview

Table 107. Hengrui Medicine Immune Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 108. Hengrui Medicine Immune Checkpoint Inhibitors Product

Table 109. Hengrui Medicine Recent Developments/Updates

Table 110. Junshi Biosciences Company Information

Table 111. Junshi Biosciences Description and Business Overview

Table 112. Junshi Biosciences Immune Checkpoint Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 113. Junshi Biosciences Immune Checkpoint Inhibitors Product

Table 114. Junshi Biosciences Recent Developments/Updates

Table 115. Key Raw Materials Lists

Table 116. Raw Materials Key Suppliers Lists

Table 117. Immune Checkpoint Inhibitors Distributors List

Table 118. Immune Checkpoint Inhibitors Customers List

Table 119. Immune Checkpoint Inhibitors Market Trends

Table 120. Immune Checkpoint Inhibitors Market Drivers

Table 121. Immune Checkpoint Inhibitors Market Challenges

Table 122. Immune Checkpoint Inhibitors Market Restraints

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. Product Picture of Immune Checkpoint Inhibitors

Figure 2. Global Immune Checkpoint Inhibitors Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Immune Checkpoint Inhibitors Market Share by Type: 2024 & 2031

Figure 4. PD-1/PD-L1 Product Picture

Figure 5. CTLA-4 Product Picture

Figure 6. Global Immune Checkpoint Inhibitors Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Immune Checkpoint Inhibitors Market Share by Application: 2024 & 2031

Figure 8. Lung Cancer

Figure 9. Colorectal Cancer

Figure 10. Breast Cancer

Figure 11. Prostate Cancer

Figure 12. Melanoma

Figure 13. Blood Cancer

Figure 14. Other

Figure 15. Global Immune Checkpoint Inhibitors Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 16. Global Immune Checkpoint Inhibitors Market Size (2020-2031) & (US$ Million)

Figure 17. Global Immune Checkpoint Inhibitors Sales (2020-2031) & (K Units)

Figure 18. Global Immune Checkpoint Inhibitors Average Price (USD/Unit) & (2020-2031)

Figure 19. Immune Checkpoint Inhibitors Report Years Considered

Figure 20. Immune Checkpoint Inhibitors Sales Share by Manufacturers in 2024

Figure 21. Global Immune Checkpoint Inhibitors Revenue Share by Manufacturers in 2024

Figure 22. Global 5 and 10 Largest Immune Checkpoint Inhibitors Players: Market Share by Revenue in Immune Checkpoint Inhibitors in 2024

Figure 23. Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 24. Global Immune Checkpoint Inhibitors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 25. North America Immune Checkpoint Inhibitors Sales Market Share by Country (2020-2031)

Figure 26. North America Immune Checkpoint Inhibitors Revenue Market Share by Country (2020-2031)

Figure 27. U.S. Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. Canada Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Europe Immune Checkpoint Inhibitors Sales Market Share by Country (2020-2031)

Figure 30. Europe Immune Checkpoint Inhibitors Revenue Market Share by Country (2020-2031)

Figure 31. Germany Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. France Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. U.K. Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Italy Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Russia Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Asia Pacific Immune Checkpoint Inhibitors Sales Market Share by Region (2020-2031)

Figure 37. Asia Pacific Immune Checkpoint Inhibitors Revenue Market Share by Region (2020-2031)

Figure 38. China Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Japan Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. South Korea Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. India Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Australia Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Taiwan Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Indonesia Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Thailand Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Malaysia Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Philippines Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Latin America Immune Checkpoint Inhibitors Sales Market Share by Country (2020-2031)

Figure 49. Latin America Immune Checkpoint Inhibitors Revenue Market Share by Country (2020-2031)

Figure 50. Mexico Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Brazil Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Argentina Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Middle East and Africa Immune Checkpoint Inhibitors Sales Market Share by Country (2020-2031)

Figure 54. Middle East and Africa Immune Checkpoint Inhibitors Revenue Market Share by Country (2020-2031)

Figure 55. Turkey Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. Saudi Arabia Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. U.A.E Immune Checkpoint Inhibitors Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 58. Global Sales Market Share of Immune Checkpoint Inhibitors by Type (2020-2031)

Figure 59. Global Revenue Market Share of Immune Checkpoint Inhibitors by Type (2020-2031)

Figure 60. Global Immune Checkpoint Inhibitors Price (USD/Unit) by Type (2020-2031)

Figure 61. Global Sales Market Share of Immune Checkpoint Inhibitors by Application (2020-2031)

Figure 62. Global Revenue Market Share of Immune Checkpoint Inhibitors by Application (2020-2031)

Figure 63. Global Immune Checkpoint Inhibitors Price (USD/Unit) by Application (2020-2031)

Figure 64. Immune Checkpoint Inhibitors Value Chain

Figure 65. Channels of Distribution (Direct Vs Distribution)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions